{"name":"Fate Therapeutics, Inc.","slug":"fate","ticker":"FATE","exchange":"NASDAQ","domain":"fatetherapeutics.com","description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.","hq":"San Diego, CA","founded":0,"employees":"161","ceo":"Scott Wolchko","sector":"Cell & Gene Therapy","stockPrice":2,"stockChange":-0.13,"stockChangePercent":-6.1,"marketCap":"$232M","metrics":{"revenue":6646000,"revenueGrowth":-20.3,"grossMargin":0,"rdSpend":107829000,"netIncome":-136315000,"cash":174822000,"dividendYield":0,"peRatio":-1.9,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Fate Therapeutics reported its financial results for the fourth quarter and full year 2023, highlighting progress in its clinical pipeline and strong cash position.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"Fate Therapeutics Announces Collaboration with Pfizer to Develop Cell Therapies for Cancer","summary":"Fate Therapeutics entered into a collaboration with Pfizer to develop cell therapies for the treatment of cancer, leveraging Fate's proprietary platforms and Pfizer's expertise in oncology.","drugName":"","sentiment":"positive"},{"date":"2023-09-25","type":"trial","headline":"Fate Therapeutics Announces Positive Interim Results from Phase 1 Clinical Trial of FT596","summary":"Fate Therapeutics reported positive interim results from a Phase 1 clinical trial of FT596, a cell therapy being developed for the treatment of B-cell malignancies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPSmJFcnZnVFVCa0tFT2VJb2kyOVlpWE1YajZSOVZnVWJfR0dVTUlka0ZwTVZKSnNmeG42NjhmbFFTM18xa1ZrWWRSTWNFWnBTdk41NUlKaGVrbC10UG9ycks5NGNWVWtubDJKT24wdHYzaFRDaDgyLWgzTTdqdS1nS1ZNbjZuSWlVT1lSWUlBWFdmek5pdGx6ajQ2TFR4MFVyN3JnZW5QUVJFdHZIM2ZLUC05UlR0SlVFMm5pRF9aT2d5LWtIS3ROLXQ4RlBhbEtoNEdwS2IyZG9vbFNMaFpqR2JGWDFTUTN3SHZIVUNpR1NLam1UM2lqMHdR?oc=5","date":"2026-04-02","type":"pipeline","source":"GlobeNewswire","summary":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire","headline":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPY2JUTjZEMTZSaEFiUkl1S1dkbFBjd25QN09QbDRYYjVwSXNwN0MtUlEyTmRmZGZPZkpfVjUzY1ZpRFNSbHhMOXRPX05hZ0ZBY1ZYZWpCQ1hKeFhkVXZFMnJDd211V19YcHhaRTlUb19CMHAxdGpXS2hwT29rN1RrT1dMdUsxTDU0OE9BUTJFUng5QllNdmVrQmMzY1JkNVFVZllFQjVRUWllUGd2SE1sSnB2b1pqMjduN0ZUOXlGYmNxN2M?oc=5","date":"2026-03-21","type":"pipeline","source":"AD HOC NEWS","summary":"Fate Therapeutics Inc stock faces analyst caution amid biotech pipeline scrutiny - AD HOC NEWS","headline":"Fate Therapeutics Inc stock faces analyst caution amid biotech pipeline scrutiny","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-27","type":"earnings","source":"simplywall.st","summary":"Fate Therapeutics FY 2025 Loss Reduction Tests Bullish Narratives On Path To Profitability - simplywall.st","headline":"Fate Therapeutics FY 2025 Loss Reduction Tests Bullish Narratives On Path To Profitability","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOU3hfa0JPVU9zTXZWc1A0WkRUYVhLZlB3c1RPc1FxVU1mSFBlN0lQT0tOMHlvbXJwRlZMbFhxdV9zTkxfWXBkUFdGcWZaQkFRMHpNMWFvUGpTVjlHZzluYXp4QXI5TlJrT0NXR2JwMGFrd3hZeFdyUzVuR0NuZnVuSkEzdjRRUEFqWXhPUjhsRXBEeUFIZl9jLVc1VVoyaHRmWFRVTWw0S3pFOV9xMlYzU2RpR2ZEV1dieWpjRTd4eElFY2V6UkdhdWNOd0NUUXk1Um95SjhVNHRRRUxXNGtzc2d4a2NkcjN3YmlUWEZCWTlkc2U4YlNyMW50XzFzdw?oc=5","date":"2026-02-16","type":"trial","source":"investingnews.com","summary":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - investingnews.com","headline":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZklZNXBBSi1YalNSSHVTTU9UaEFqZmtjUS1ybUliaG1RUXp0bEQtX1ZuVEN3c0RMY0ZIUlJGR0lzMldWZWZlUGhQTlVRcEgzTGFaQWw5cTFQTmVEQzF2bFVBY3luMU5fa0FuQjNyR2V0WXFZNjFpQ21DTmh5YmxKZ0RKMW1mNHlJcjdoZXBNUWpDcll1T2d0elpoY2NQZDNkeUVJQVY3cjluYnhHN3MyUkM0REJxUkZlQ2hr?oc=5","date":"2026-02-11","type":"trial","source":"Fierce Biotech","summary":"'The only thing that saves us is data': Allogeneic CAR-T biotechs fight for relevance as industry moves on - Fierce Biotech","headline":"'The only thing that saves us is data': Allogeneic CAR-T biotechs fight for relevance as industry moves on","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-17","type":"pipeline","source":"simplywall.st","summary":"Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year - simplywall.st","headline":"Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxObmR6RE1DT3FwUDVEZ3Nia0FOWXJpRTM5b2JrbVdHMDNWV0Q5MXVleGZVV0FuVjh1Q2lvSWMxUXNUMkE2MGRoRkw0N0hRbmtwTGtNT2pVbm1NZ3BYbnZQbkpuMUYtLXNRVXV0c3hlVmJiZW8wUlBLc2R0V2hVOGxYZzFRZ2lrVG9lc3AxcXdTZ0ppZ1RoeS00WU5vMDRHaHRNNVVLVnFvWGwzNmVEVEE?oc=5","date":"2025-08-29","type":"pipeline","source":"Seeking Alpha","summary":"Fate Therapeutics: Recent Update Met With Selling, But Positives Exist - Seeking Alpha","headline":"Fate Therapeutics: Recent Update Met With Selling, But Positives Exist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNdF9jYmhXZW1yS1JZaGpIODVBT1hob09MUFlJam9PNnFRNEtvb0VKaUFjck9zT3NyOV9CdDA5cVc3RW1VQ2tXNk45azZEQmdiVDh2bnEzQ044aEpBNll1clgyaGNpcUNpcUF4Z2ZhazVJMUxtekFrdnVLSFNKT3VGT012RTMyYU5jUWhtR1BKWjY5a3pKbnhWNmVKZ3ZCZlQtUHo0aXpFb2lBeW1pRmw3cXU0cHJfS1RVNEdsS3U1Z2tVTDVsMkhwOGpCM1VYaGlPSy1rVGVVMWxmY19jMHRKLTh6Z1JxTnl6bjlUMTBB?oc=5","date":"2025-08-14","type":"pipeline","source":"Investing.com","summary":"Fate Therapeutics’ SWOT analysis: biotech stock navigates clinical progress amid financial challenges - Investing.com","headline":"Fate Therapeutics’ SWOT analysis: biotech stock navigates clinical progress amid financial challenges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOGZ0azlUZ0Zlam02TnFvZnJuZGtVVzBTUDJ3Z3dObkEwTk1MRGpMYkNHdGVJTUwzWTdFaE11X0VPUXJ2ZkdidE9HVDR3U3ljT0pYYWV6eXpyU3QtNS1UVy02UU54MklrNlA2SURqSEhHVUJZNTA4VDU5clBMekIzSTQwLU1uZGZzSXdSR3E1ampHS0hGOUgzMmVZT0JtMjYzQ3g5TUdKYkl6QQ?oc=5","date":"2025-08-14","type":"pipeline","source":"Pharmaceutical Executive","summary":"Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize - Pharmaceutical Executive","headline":"Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["CRISPR Therapeutics","Editas Medicine","uniQure"],"therapeuticFocus":["Oncology","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":6646000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":6646000,"period":"2025-12-31"},{"value":13631000,"period":"2024-12-31"},{"value":13631000,"period":"2024-12-31"},{"value":63533000,"period":"2023-12-31"},{"value":63533000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":107829000,"rdSpendHistory":[{"period":"2025-12-31","value":107829000},{"period":"2024-12-31","value":135001000},{"period":"2023-12-31","value":172596000},{"period":"2022-12-31","value":320454000}],"sgaSpend":46521000,"operatingIncome":-147704000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-147704000},{"period":"2024-12-31","value":-195539000},{"period":"2023-12-31","value":-190511000},{"period":"2022-12-31","value":-308386000}],"netIncome":-136315000,"netIncomeHistory":[{"period":"2025-12-31","value":-136315000},{"period":"2024-12-31","value":-186262000},{"period":"2023-12-31","value":-160928000},{"period":"2022-12-31","value":-281721000}],"eps":-1.15,"epsHistory":[{"period":"2025-12-31","value":-1.15},{"period":"2024-12-31","value":-1.64},{"period":"2023-12-31","value":-1.64},{"period":"2022-12-31","value":-2.91}],"cash":46628000,"cashHistory":[{"period":"2025-12-31","value":46628000},{"period":"2024-12-31","value":36056000},{"period":"2023-12-31","value":41870000},{"period":"2022-12-31","value":61333000}],"totalAssets":318937000,"totalLiabilities":111753000,"totalDebt":77849000,"equity":207184000,"operatingCashflow":-106084000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-106084000},{"period":"2024-12-31","value":-122874000},{"period":"2023-12-31","value":-132263000},{"period":"2022-12-31","value":-248208000}],"capex":-5953000,"capexHistory":[{"period":"2025-12-31","value":-5953000},{"period":"2024-12-31","value":-730000},{"period":"2023-12-31","value":-6153000},{"period":"2022-12-31","value":-35566000}],"freeCashflow":-112037000,"dividendsPaid":null,"buybacks":null,"employees":161,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":10665000,"ebit":-34721000,"ebitda":-31658000,"period":"2025-12-31","revenue":1369000,"epsBasic":-0.27,"netIncome":-32374000,"rdExpense":25425000,"epsDiluted":-0.27,"grossProfit":null,"operatingIncome":-34721000},{"sga":10638000,"ebit":-34735000,"ebitda":-31508000,"period":"2025-09-30","revenue":1741000,"epsBasic":-0.27,"netIncome":-32250000,"rdExpense":25838000,"epsDiluted":-0.27,"grossProfit":null,"operatingIncome":-34735000},{"sga":11445000,"ebit":-36968000,"ebitda":-33690000,"period":"2025-06-30","revenue":1907000,"epsBasic":-0.29,"netIncome":-34070000,"rdExpense":27430000,"epsDiluted":-0.29,"grossProfit":null,"operatingIncome":-36968000},{"sga":13773000,"ebit":-41280000,"ebitda":-37947000,"period":"2025-03-31","revenue":1629000,"epsBasic":-0.32,"netIncome":-37621000,"rdExpense":29136000,"epsDiluted":-0.32,"grossProfit":null,"operatingIncome":-41280000},{"sga":15262000,"ebit":-47011000,"ebitda":-42198000,"period":"2024-12-31","revenue":1860000,"epsBasic":-0.44,"netIncome":-52153000,"rdExpense":33609000,"epsDiluted":-0.44,"grossProfit":null,"operatingIncome":-47011000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2,"previousClose":2.13,"fiftyTwoWeekHigh":2.47,"fiftyTwoWeekLow":0.91,"fiftyTwoWeekRange":"0.91 - 2.47","fiftyDayAverage":1.41,"twoHundredDayAverage":1.22,"beta":0,"enterpriseValue":150819856,"forwardPE":-1.9,"priceToBook":1.29,"priceToSales":36.73,"enterpriseToRevenue":23.88,"enterpriseToEbitda":-1.2,"pegRatio":0,"ebitda":-125838000,"ebitdaMargin":0,"freeCashflow":-46616500,"operatingCashflow":-103097000,"totalDebt":76785000,"debtToEquity":42.7,"currentRatio":5.85,"returnOnAssets":-25.3,"returnOnEquity":-55.5,"analystRating":"2.2 - Buy","recommendationKey":"buy","numberOfAnalysts":8,"targetMeanPrice":5.44,"targetHighPrice":8,"targetLowPrice":2,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.2,"institutionHeldPercent":80.8,"sharesOutstanding":116281693,"floatShares":102431047,"sharesShort":10255224,"shortRatio":8.9,"shortPercentOfFloat":8.8,"epsTrailing":-1.15,"epsForward":-1.04,"revenuePerShare":0.05,"bookValue":1.55,"officers":[{"age":48,"name":"Dr. Bahram  Valamehr M.B.A., Ph.D.","title":"President, CEO & Director"},{"age":46,"name":"Mr. Kamal  Adawi M.S., MBA","title":"CFO & Treasurer"},{"age":52,"name":"Ms. Cindy R. Tahl J.D.","title":"Chief Legal & Compliance Officer and Corporate Secretary"},{"age":null,"name":"Ms. Jessica  Francis","title":"Senior Vice President of Human Resources & Operations"},{"age":null,"name":"Dr. Martin  Hosking","title":"Head of Research"},{"age":null,"name":"Dr. Tunde  Babalola Ph.D.","title":"Senior Vice President of Technical Operations & Quality"},{"age":null,"name":"Mr. Ryan  Douglas","title":"Senior Director of Investor Relations & Business Development"},{"age":61,"name":"Mr. Andrew  Henry","title":"Senior Vice President of Clinical Operations"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.fatetherapeutics.com","phone":"858 875 1800"}}